Oculis Completes Randomization in Licaminlimab PREDICT-1 Trial
Oculis said randomization is complete in its registrational trial of licaminlimab for TNFR1-mediated dry eye disease. Two-thirds of the 176 enrolled patients carry the TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials.
Story updates
06:01:41 AM UTC
SquawkNews
Oculis completed randomization of 176 patients in its genotyped PREDICT-1 registrational trial of Licaminlimab for dry eye disease, with topline data expected around end-2026; about two-thirds carry the specified TNFR1 genotype.Material DetailsContext by AI AnalystThis is a mid-stage development mi…